High-Dose Therapy and Breast Cancer Prognosis
Author Information
Author(s): Hohaus S, Funk L, Martin S, Schlenk R F, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiß A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R
Primary Institution: Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Hypothesis
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Conclusion
Sequential high-dose chemotherapy with PBSC support can be safely administered to patients with high-risk stage II/III breast cancer.
Supporting Evidence
- The probability of disease-free survival at 4 years was 60%.
- The probability of overall survival at 4 years was 83%.
- Patients with stage II disease had a significantly better probability of disease-free survival (74%) compared to stage III disease (36%).
- Patients with oestrogen receptor-positive tumours had a better probability of disease-free survival (70%) compared to receptor-negative ones (40%).
Takeaway
This study looked at how well a strong cancer treatment works for women with serious breast cancer. It found that some women do better than others based on their cancer stage and hormone levels.
Methodology
Patients received high-dose chemotherapy with PBSC support after induction therapy, and their outcomes were evaluated.
Limitations
The study may not fully account for all variables affecting prognosis, and the sample size may limit generalizability.
Participant Demographics
Patients with high-risk stage II/III breast cancer, including 71 with more than nine tumour-positive axillary lymph nodes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website